Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Congress 2022

Poster viewing 03

266P - Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib

Date

03 Dec 2022

Session

Poster viewing 03

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Xuchao Zhang

Citation

Annals of Oncology (2022) 33 (suppl_9): S1533-S1539. 10.1016/annonc/annonc1130

Authors

X. Zhang1, Y. Wu2, Y. Chen3, H. Zhang4, G. Wu5, Y. Lu6, Z. Liang7, Y. Hu8, Y. Cheng9, J. Wang10, J. Ying11, W. Liu12, Z. Liang13

Author affiliations

  • 1 Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, 510030 - Guangzhou/CN
  • 2 Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, 510080 - Guangzhou/CN
  • 3 Department Of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030 - Wuhan/CN
  • 4 Department Of Oncology, Tangdu Hospital, Fourth Military Medical University,, 710038 - Xi'an/CN
  • 5 Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology., 430022 - Wuhan/CN
  • 6 Department Of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University., 610041 - Chengdu/CN
  • 7 Department Of Respiratory And Critical Care Medicine, West China Hospital, Sichuan University., 610065 - Chengdu/CN
  • 8 Department Of Oncology, Hubei Cancer Hospital., 430079 - Wuhan/CN
  • 9 Medical Oncology, Jilin Provincial Cancer Hospital., 130000 - Changchun/CN
  • 10 Medical Oncology Dept., National Cancer Centre, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 - Beijing/CN
  • 11 Department Of Pathology, National Cancer Centre, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College., 100021 - Beijing/CN
  • 12 Department Of Pathology, West China Hospital, Sichuan University., 610041 - Chengdu/CN
  • 13 Department Of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences., 100730, - Beijing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Abstract 266P

Background

We analysed dynamic mutation profiles of next-generation sequencing (NGS) T790M+ advanced non-small cell lung cancer (NSCLC) patients from an open-label, multicentre study (ADELOS, NCT02997501) in China.

Methods

T790M+ patients pre-treated with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), received osimertinib 80 mg/day orally till disease progression (PD). Progression-free survival (PFS) was defined as the time from treatment to PD/death. NGS (168-gene panel) was used as one of four methods to identify T790M at baseline and monitor mutation status in circulating tumour DNA (ctDNA) from different timepoints.

Results

Among 167 T790M+ patients receiving osimertinib, 129 were T790M+ by NGS (NGS+) and 89 were T790M+ by Cobas (Cobas+) at baseline. Median PFS (mPFS) (95% CI) of NGS+ and Cobas+ was 11.0 (9.5-13.8) and 10.6 (8.5-13.8) months, respectively, while 40 T790M- by Cobas in NGS+ had mPFS of 11.3 (8.3-NA) months. In NGS+, 62 had EGFR only (19del, L858R or any uncommon mutation), 54 had tumour suppressor only (TP53, RB1 and PTEN) and 13 had multiple driver (KRAS, MET amp, BRAF V600E, HER2 amp, ROS1 fusion, ALK fusion and RET fusion) with mPFS of 15.0 (9.72-NE), 9.1 (7.06-10.97) and 7.6 (2.23-15.41) months, respectively. T790M/EGFR mutations (T790M, G719X, L858R, 19del, L816Q, 20ins, S768I, C797S) clearance at treatment week 6 and best response and presence of T790M at PD were associated with longer PFS (Table). Table: 266P

mPFS by EGFR/T790M mutation status

T790M+ T790M- P-value EGFR+ EGFR- P-value
Months (95% CI) Treatment Week 6 7.5 (4.0-15.3) 11.0 (9.5-15.0) 0.0441 6.7 (4.5-8.5) 15.0 (11.1-NA) <0.0001
Best response 6.7 (1.2-12.4) 11.0 (9.5-15.0) 0.0026 6.4 (4.5-8.5) 15.0 (10.7-NA) <0.0001
Before PD 8.7 (4.0-13.8) 8.3 (6.4-8.5) 0.3337 8.2 (6.4-8.5) 9.7 (4.6-11.1) 0.8225
PD 12.4 (6.8-15.1) 8.3 (5.4-9.5) 0.0264 8.4 (6.8-10.5) 9.5 (2.9-11.0) 0.2687

Conclusions

Co-mutation (multiple driver and tumour suppressor) at baseline and early clearance of T790M/EGFR mutations were corelated with efficacy and could be prognostic factors of osimertinib treatment. NGS might increase the population base that could benefit from osimertinib due to detection of low frequency mutations.

Clinical trial identification

NCT02997501.

Editorial acknowledgement

Indegene Pvt. Ltd.

Legal entity responsible for the study

Xuchao Zhang.

Funding

AstraZeneca China.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.